In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

The Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...

Nearly a year after new sickle cell gene therapies were approved, CNBC's Bertha Coombs reports a small number of patients are ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

On a family vacation, 14-year-old Jaden Hartley discovered he needed a heart transplant after experiencing this symptom. Now ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

As treatment and care continues to evolve, we must ensure that people living with this disease are able to advocate for ...

Scott Turner Department of Housing and Urban Development secretary, announced a new Department of Government Efficiency Task ...

“We still have a serious challenge with sickle cell disease, which contributes to 20% of under-five mortality every year.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.